Fibroblast to Myofibroblast Transition (FMT) Assay Services
From Lung Airway Models Services
In vitro assessment of Fibroblast-to-Myofibroblast transition (FMT). Newcells offers a fast and reliable FMT assay service to evaluate the efficacy of anti-fibrotic compounds using high-content imaging. This customisable, high-throughput assay is well suited to compound screening for small molecules targeting lung fibrosis. Normal repair processes are defective in the fibrotic lung. Repetitive cellular microinjuries and a heightened immune response leads to chronic activation of fibroblasts. Activated fibroblasts differentiate into myofibroblasts, a process known as fibroblast-to-myofibroblast transition (FMT). This persistent myofibroblast phenotype leads to an increased synthesis of extracellular matrix proteins, and their deposition within the lung parenchyma, causing progressive scarring, increased lung stiffness and a loss in lung function.
Details
- Cell number (nuclei staining)
- Active cell proliferation (EdU incorporation)
- Deposition of Collagen I and Collagen III by immunocytochemistry
- Detection of α-SMA
Assays
- Fibroblast-to-Myofibroblast Transition (FMT) assay
- Primary human lung fibroblasts
- 2-4 months
Newcells FMT Assay
Accelerate your lead compound selection by understanding their mode of action in a model of lung fibrosis
- Evaluate therapeutic candidates targeting idiopathic pulmonary fibrosis (IPF)
- Easily model lung fibrosis in vitro
- Accelerate drug discovery
Customer reviews
No reviews were found for Fibroblast to Myofibroblast Transition (FMT) Assay Services. Be the first to review!